Sheena X. Wang is an Associate at Rothwell, Figg, Ernst and Manbeck, P.C. She focuses her practice on assisting companies in the pharmaceutical and biotech fields with patent prosecution, post-grant proceedings, and patent litigation matters. Ms. Wang’s extensive real-world experience at leading life sciences companies, in addition to her Masters of Science in Biotechnology, lay a strong foundation for her practice.
Ms. Wang’s work experience includes various hands-on roles at Regeneron Pharmaceuticals, Inc., Synexus Clinical Research Ltd., and Novavax Inc., among others. As an intellectual property graduate intern at Regeneron Pharmaceuticals, she researched, analyzed, and presented data on the patent landscape of viral vector technologies in addition to conducting pre-filing research for upcoming inter partes review proceedings. At Synexus Clinical Research, she was a clinical laboratory associate and documented information and processed laboratory specimen for phase III clinical trials, and at Novavax, in her role as an analytical development intern, she developed standard operating procedures and identified critical reagents for the development of vaccines.
Ms. Wang was a Summer Associate at Rothwell Figg in 2020 while earning her J.D. from Washington and Lee University School of Law. While at law school, she was a Lead Articles Editor of the German Law Journal and the Intellectual Property Chair of the Sports, Entertainment, and Intellectual Property Law Society (SEIPLS). In her final year at law school she completed an internship at the U.S. Court of Appeals for the Federal Circuit. She has an undergraduate degree from the University of Western Ontario where she double majored in cell biology and genetics, as well as a Masters of Science in Biotechnology from Johns Hopkins University.
This article, originally published on 12/27/2021, was updated on 1/12/2022 and republished on 1/13/2022 to include information that was omitted in error, beginning after “Conclusions and Outlook”.
In Part I of this post, we provided an update on three lead pioneers in the mRNA IP space, Moderna, BioNTech and CureVac. In this post we profile Sanofi, Arcturus, eTheRNA and other mRNA companies and offer conclusions. Sanofi (NASDAQ: SNY), headquartered in Paris, FR, acquired mRNA pioneer Translate Bio in September 2021 for approximately $3.2 billion and mRNA startup Tidal Therapeutics in April 2021 for approximately $470 million. With its acquisition of Translate alone, Sanofi obtained an mRNA pipeline of nine candidates (two in the clinic), hundreds of patents, and undoubtedly valuable mRNA-based technical and regulatory know-how.
In April of this year, we provided a three-part series relating to the IP and Competitive Landscape for the mRNA market. In this post (Part I), we provide a 2021 year in review update on mRNA pioneers Moderna, BioNTech and CureVac, and in Part II, we profile Sanofi and other companies in the mRNA space and offer additional conclusions and outlook for 2022 and beyond.